No new approvals, withdrawals or safety communications affecting psychiatric practice today, and no new guidance from the American Psychiatric Association, NICE or the Indian Psychiatric Society since the last edition.
The standing positions most likely to come under review are unchanged. Clozapine monitoring requirements continue to differ substantially between jurisdictions after the US moved to remove its REMS programme, without a corresponding change in India or the UK. Esketamine remains restricted to supervised administration everywhere it is licensed. And the labelling on antidepressants in young people continues to carry suicidality warnings whose evidence base has been contested since they were introduced.
A quiet day reported as quiet is more useful than a manufactured item. Where the paediatric anxiety trial above is directly relevant is that its null result across modalities gives a clinician more room to follow a family's preference without departing from any guidance — the guidance does not mandate a first-line choice these data would contradict.
- No new approvals, recalls or safety communications for psychiatry today
- Clozapine monitoring requirements still diverge between jurisdictions
- Esketamine remains restricted to supervised administration
- No change to paediatric antidepressant labelling
- Today's paediatric anxiety data sit comfortably within existing guidance
The statistics, in plain English
No effect estimate applies to a regulatory null. The value of reporting one is that the absence is checked rather than assumed — a day with no regulatory news and a day nobody looked are indistinguishable to a reader unless someone says which it was.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free